<DOC>
	<DOCNO>NCT00611910</DOCNO>
	<brief_summary>The aim study compare efficacy drug-eluting stent bare metal stent reduce reblockage bypass graft coronary stenting</brief_summary>
	<brief_title>Efficacy Study Drug-eluting Bare Metal Stents Bypass Graft Lesions</brief_title>
	<detailed_description>A large number study show drug-eluting stent significantly reduce in-stent restenosis subsequent need target vessel revascularisation compare bare metal stent . Although applies vast majority patient , intimal hyperplasia in-stent restenosis completely eliminate remain occur certain high risk subgroup . While plenty data efficacy DES complex lesion diabetic , randomize data exist efficacy DES coronary artery bypass graft lesion .</detailed_description>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients old age 18 ischemic symptom evidence myocardial ischemia presence â‰¥ 50 % de novo stenosis locate CABG Written , inform consent patient her/his legallyauthorized representative participation study . In woman childbearing potential negative pregnancy test mandatory Cardiogenic shock Target lesion locate native coronary vessel . Instent restenosis CABG Target lesion locate internal mammary artery graft free arterial graft Malignancies comorbid condition ( example severe liver , renal pancreatic disease ) life expectancy le 12 month may result protocol noncompliance . Known allergy study medication : clopidogrel , rapamycin , paclitaxel , stainless steel . Inability take clopidogrel least 6 month . Pregnancy ( present , suspected plan ) positive pregnancy test . Previous enrollment trial . Patient 's inability fully cooperate study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>